Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.

Abstract

BACKGROUND:

Despite high vaccine coverage and effectiveness, the incidence of symptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been increasing in Israel. Whether the increasing incidence of infection is due to waning immunity after the receipt of two doses of the BNT162b2 vaccine is unclear.

METHODS:

We conducted a 6-month longitudinal prospective study involving vaccinated health care workers who were tested monthly for the presence of anti-spike IgG and neutralizing antibodies. Linear mixed models were used to assess the dynamics of antibody levels and to determine predictors of antibody levels at 6 months.

RESULTS:

The study included 4868 participants, with 3808 being included in the linear mixed-model analyses. The level of IgG antibodies decreased at a consistent rate, whereas the neutralizing antibody level decreased rapidly for the first 3 months with a relatively slow decrease thereafter. Although IgG antibody levels were highly correlated with neutralizing antibody titers (Spearman's rank correlation between 0.68 and 0.75), the regression relationship between the IgG and neutralizing antibody levels depended on the time since receipt of the second vaccine dose. Six months after receipt of the second dose, neutralizing antibody titers were substantially lower among men than among women (ratio of means, 0.64; 95% confidence interval [CI], 0.55 to 0.75), lower among persons 65 years of age or older than among those 18 to less than 45 years of age (ratio of means, 0.58; 95% CI, 0.48 to 0.70), and lower among participants with immunosuppression than among those without immunosuppression (ratio of means, 0.30; 95% CI, 0.20 to 0.46).

CONCLUSIONS:

Six months after receipt of the second dose of the BNT162b2 vaccine, humoral response was substantially decreased, especially among men, among persons 65 years of age or older, and among persons with immunosuppression.

• Authors: Einav G Levin, Yaniv Lustig, Carmit Cohen, Ronen Fluss, Victoria Indenbaum, Sharon Amit, Ram Doolman, Keren Asraf, Ella Mendelson, Arnona Ziv, Carmit Rubin, Laurence Freedman, Yitshak Kreiss, Gili Regev-Yochay
• Journal: The New England journal of medicine (N Engl J Med) Vol. 385 Issue 24 Pg. e84 (12 09 2021) ISSN: 1533-4406 [Electronic] United States
• PMID: 34614326 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Massachusetts Medical Society.

Chemical References

• Antibodies, Neutralizing
• Antibodies, Viral
• Immunoglobulin G
• BNT162 Vaccine

Topics

• Adult
• Age Factors
• Aged
• Antibodies, Neutralizing (blood)
• Antibodies, Viral (blood)
• BNT162 Vaccine (immunology)
• Body Mass Index
• COVID-19 (immunology, prevention & control)
• Cohort Studies
• Female
• Health Personnel
• Humans
• Immunization, Secondary
• Immunocompromised Host
• Immunogenicity, Vaccine
• Immunoglobulin G (blood)
• Israel
• Linear Models
• Male
• Middle Aged
• Sex Factors
• Time Factors
• Vaccine Efficacy